Apple is using on-device AI to reduce the friction of creating tasks. The new feature in Reminders scans selected text for actions and dates, promising to save time. But it has some significant hardware and language limitations.
Solana Mobile is launching a new token, SKR, to support its open mobile platform centered on the Seeker smartphone. The fixed supply of 10 billion tokens will be used for staking and governance, managed by a group called Guardians starting in 2026.
Roku plans to take its budget-friendly, ad-free Howdy streaming service to other platforms. Launched last August for $2.99 a month, it targets a market gap left by pricier competitors. The CEO says they want to distribute it “everywhere.”
At CES, Dell’s head of product admitted the company shifted its marketing away from an “AI-first” message. He said consumers aren’t buying based on AI and that the term probably confuses them more than it helps.
A joint venture led by Italian cable giant Prysmian has agreed to buy subsea telecom systems provider Xtera. The deal, valued at $65 million, is expected to close in early 2026 and signals a major push into the AI-driven cable market.
Samsung’s president says semiconductor supply issues and rising prices will force the company to consider repricing its products. This comes as Samsung aims to double its AI-powered devices to 800 million this year.
According to CNBC, Nvidia has unveiled its next-generation Rubin (R100) AI architecture, locking in its roadmap through 2027. The analysis highlights Nvidia’s exceptional growth metrics and presents a bullish options trade targeting a move to $220-$250.
A pro-Russian hacktivist group is coordinating sustained denial-of-service attacks using a volunteer botnet. Their tool, DDoSia, allows anyone to join in, turning geopolitical tension into disruptive cyber campaigns. It’s more about persistent harassment than outright destruction.
Meta’s planned $2 billion acquisition of AI startup Manus is facing a review by Chinese regulators. The concern is whether the deal violates the country’s technology export controls, even though Manus has since moved to Singapore.
In a major move for precision oncology, Amgen is acquiring UK biotech Dark Blue Therapeutics. The deal, valued at up to €718 million, centers on a promising leukemia drug candidate currently in pre-clinical studies.
